Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).-Reference-Cited by-同舟云学术

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

Published:2018-06-29 Issue:3 Volume:119 Page:330-338
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Ruscito Ilary,Cacsire Castillo-Tong Dan,Vergote Ignace,Ignat Iulia,Stanske Mandy,Vanderstichele Adriaan,Glajzer Jacek,Kulbe Hagen,Trillsch Fabian,Mustea Alexander,Kreuzinger Caroline,Benedetti Panici Pierluigi,Gourley Charlie,Gabra Hani,Nuti Marianna,Taube Eliane T.,Kessler Mirjana,Sehouli Jalid,Darb-Esfahani Silvia,Braicu Elena Ioana

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0157-z.pdf

Reference42 articles.

1. Levanon, K., Crum, C. & Drapkin, R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 26, 5284–5293 (2008).

2. Li, J., Fadare, O., Xiang, L., Kong, B. & Zheng, W. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J. Hematol. Oncol. 5, 8 (2012).

3. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 .

4. Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668–679 (2015).

5. Burger, R. A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 365, 2473–2483 (2011).

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach;Nature Reviews Clinical Oncology;2024-09-04

2. Feasibility of iodine concentration parameter and extracellular volume fraction derived from dual-energy CT for distinguishing type Ⅰ and type Ⅱ epithelial ovarian carcinoma;2024-06-25

3. Microvessel Density Assessment in Gynecological Malignancies;Indian Journal of Gynecologic Oncology;2024-05-07

4. AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication;British Journal of Cancer;2024-02-09

5. Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system;Frontiers in Genetics;2022-09-09